drugset / Trial / NCT04030546
Ivabradine to Prevent Anthracycline-induced Cardiotoxicity
RandomizedParallel-groupSingle-blindTreatment
Summary
The aim of this study is to investigate protective effects of ivabradine in adult cancer patients undergoing anthracycline-based chemotherapy.
Timeline
- Start
- 2019-06-01
- Primary completion
- 2020-06-01
- Completion
- 2020-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Ivabradine | Small molecule | 5 mg | Oral |
Indications
No indication recorded.